Sen-Jam Pharmaceutical has cleared the various regulatory
hurdles and now is actively enrolling patients in it's much
anticipated COVID oral therapeutic Clinical Trial. In addition, the
company recently entered a powerhouse strategic partnership with a
Specialty Pharmaceutical Manufacturing company, one of the largest
investors in the project to date, to help rapidly manufacture
billions of capsules annually. This is a monumental milestone for
the company and great news for their promising oral COVID-19
treatment.
HUNTINGTON, N.Y., May 6, 2022
/PRNewswire/ -- Sen-Jam Pharmaceutical, an innovative life sciences
company developing a portfolio of revolutionary anti-inflammatories
by repurposing existing molecules for novel combination therapy,
this week began enrolling patients into their Phase 2 Clinical
Trial for their promising oral COVID therapeutic. At the same time,
the company has joined forces with KVK Tech that will provide
access to world-class Formulation and Chemistry, Manufacturing
& Controls (CMC) for their COVID-19 therapeutic.
A collaborative team of scientists from several different
countries have been working tirelessly in various time zones
simultaneously to get approvals to commence the trial with the
Nepalese governing bodies since late last year. The
commitment and perseverance paid off and now they are underway
enrolling patients into their Clinical Trial. These research
efforts reflect a remarkable partnership between Sen-Jam, Duke-NUS
Medical School, Duke University School
of Medicine, and Global Clinical Research, which combined, makes up
an esteemed group of international researchers.
Sen-Jam's investigational therapeutic for the treatment of
COVID-19, SJP-002C is now actively enrolling patients for their
clinical trial under a co-development agreement with Duke-NUS and
Duke University School of Medicine. Dr.
Alexander T. Limkakeng Jr., MD, MHSc, FACEP, Professor, Vice Chief
of Research and Director, Acute Care Research at Duke Emergency
Medicine said, "The study design has several unique features,
including using a combination therapy that is widely available as
an approved drug in countries around the world; has a known safety
profile and well-understood mechanism of action of its individual
components; has been studied in other viral illnesses; and could
have complementary effects, with one agent potentially reducing the
known side effects of the other."
Kiran Vepuri, Director of Business Development for KVK-Tech,
Sen-Jam's largest Strategic investor to date, said, "This is a
fantastic fit for our organization. We pride ourselves on our
commitment to deliver safe, effective and affordable FDA-approved
pharmaceuticals to meet our customers' needs and ensure that
patients have access to high-quality medicines when they need it.
Sen-Jam and their talented team of innovators, scientists and
entrepreneurs represent a perfect fit for our culture of excellence
and our unwavering focus on delivering value."
Sen-Jam Pharmaceutical, affectionately known as the "Pharma for
the people, people," is thrilled by this move that accelerates the
advancement of these promising therapeutics. With a mission to
bring accessible, affordable, highly effective and safe solutions
to the world, this week was a massive step forward to achieving
that dream.
About Sen-Jam Pharmaceutical
At Sen-Jam
Pharmaceutical we disrupt pain and inflammation. Sen-Jam
Pharmaceutical's mission is to improve societal wellbeing by
developing therapeutics that are safe, efficacious, and accessible
by all. Sen-Jam repurposes small molecules to develop novel
therapeutics for large unmet needs with a focus on improving
clinical outcomes. Using patented proprietary technology and the
accelerated 505(b)2 pathway, Sen-Jam is on a mission to
revolutionize inflammatory pain treatment and its unwanted side
effects. Investor information available at Wefunder. Learn more at
www.sen-jam.com.
CONTACT INFORMATION:
Sen-Jam Pharmaceutical
Christine Leonard
781-913-1902
335735@email4pr.com
View original
content:https://www.prnewswire.com/news-releases/sen-jam-pharmaceutical-opens-enrollment-for-patients-in-their-covid-therapy-phase-2-clinical-trial-in-nepal-and-engages-with-strategic-investor-for-worldwide-distribution-301541414.html
SOURCE Sen-Jam Pharmaceutical
